Drug Trial Radar · NCT02999828
The Phase IVa of Inactivated Enterovirus 71 Vaccine (Human Diploid Cell, KMB-17)
Last checked: Nov 20, 2026Latest source record: Jan 23, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
20,770
Actual
Start
Sep 2016
Primary completion
Feb 2019
Study completion Feb 2019
Sponsor
- Lead sponsor
- Chinese Academy of Medical SciencesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Beijing Chaoyang District Centre for Disease Control and Prevention; Neimenggu Province Centre for Disease Control and Prevention
- First posted
- Dec 21, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 6 months, up to 71 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Enterovirus 71 (EV71), a major pathogen causing hand-foot-and-mouth disease (HFMD) worldwide, is a member of the Human Enterovirus species A, family Picornaviridae. Its infection occasionally leads to severe diseases and death, with central nervous system (CNS) damage. Recently, except of inactivated vaccine, several EV71 vaccine candidates have been evaluated in animals but no final results of clinical trials, such as attenuated vaccine, subunit vaccine. A formalin-inactivated EV71 vaccine (Human Diploid cell, KMB-17 Cell) has been finished phase I, II and III clinical trials and licensed by SFDA in China at Dec. 3, 2015. Based on the results of clinical trials, the protective efficacy of inactivated EV71 vaccine is 97% against HFMD caused by EV71. The phase IV clinical trial has been carried out from July 2016. The purpose of phase IV is to evaluated the safety and efficacy of the inactive EV71 vaccine in large scale population of Chinese children (from 6 to 71 months old).
Conditions
- Safety of Inactivated EV71 Vaccine
- Immunization of Inactivated EV71 Vaccine
Interventions
inactivated EV71 vaccine (KMB-17)Biological
3.0EU of inactivated enterovirus 71 vaccine (KMB-17) on day 0, 28.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment adverse eventsTime frame: Up to 24 months after finishing 2 doses immunization
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chaoyang of Provincial Center for Diseases Control and Prevention in Beijing
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.